JaLCDOI 10.18926/AMO/54607
FullText URL 70_5_425.pdf
Author Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
Abstract Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
Keywords breast cancer phase I trial docetaxel
Amo Type Clinical Study Protocols
Published Date 2016-10
Publication Title Acta Medica Okayama
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 425
End Page 427
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777441
Web of Sience KeyUT 000388098700018
JaLCDOI 10.18926/AMO/53907
FullText URL 69_6_333.pdf
Author Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
Abstract We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
Keywords breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features
Amo Type Original Article
Published Date 2015-12
Publication Title Acta Medica Okayama
Volume volume69
Issue issue6
Publisher Okayama University Medical School
Start Page 333
End Page 338
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26690243
Web of Sience KeyUT 000368434500002
JaLCDOI 10.18926/AMO/53675
FullText URL 69_5_291.pdf
Author Sugiu, Kumi| Iwamoto, Takayuki| Kelly, Catherine M.| Watanabe, Naoki| Motoki, Takayuki| Itoh, Mitsuya| Ohtani, Shoichiro| Higaki, Kenji| Imada, Takako| Yuasa, Takeshi| Omori, Masako| Sonobe, Hiroshi| Fujiwara, Toshiyoshi| Matsuoka, Junji|
Abstract Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
Keywords breast cancer neoadjuvant chemotherapy concurrent hormone therapy estrogen receptor positive tumor response
Amo Type Original Article
Published Date 2015-10
Publication Title Acta Medica Okayama
Volume volume69
Issue issue5
Publisher Okayama University Medical School
Start Page 291
End Page 299
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26490026
Web of Sience KeyUT 000365519600005
Author Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro|
Published Date 2013-12-01
Publication Title BMC Cancer
Volume volume13
Content Type Journal Article
Author Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos|
Published Date 2014-01
Publication Title Breast Cancer Research and Treatment
Volume volume143
Issue issue2
Content Type Journal Article
Title Alternative Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer
FullText URL 126_25.pdf
Author Mizoo, Taeko| Shien, Tadahiko| Ito, Maiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
Abstract  Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay.  Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection.  Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected.  Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery.
Keywords OSNA法(OSNA method) センチネルリンパ節(sentinel lymph node) micrometastases CK-19
Publication Title 岡山医学会雑誌
Published Date 2014-04-01
Volume volume126
Issue issue1
Start Page 25
End Page 30
ISSN 0030-1558
Related Url http://www.okayama-u.ac.jp/user/oma/
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
DOI 10.4044/joma.126.25
Author Nishikawa, Toshio| Takaoka, Munenori| Ohara, Toshiaki| Tomono, Yasuko| Hao, Huifang| Bao, Xiaohong| Fukazawa, Takuya| Wang, Zhigang| Sakurama, Kazufumi| Fujiwara, Yasuhiro| Motoki, Takayuki| Shirakawa, Yasuhiro| Yamatsuji, Tomoki| Tanaka, Noriaki| Fujiwara, Toshiyoshi| Naomoto, Yoshio|
Published Date 2013-03
Publication Title Cancer Biology & Therapy
Volume volume14
Issue issue3
Content Type Journal Article
JaLCDOI 10.18926/AMO/50407
FullText URL 67_3_145.pdf
Author Ishihara, Setsuko| Taira, Naruto| Kawasaki, Kensuke| Ishibe, Youichi| Mizoo, Taeko| Nishiyama, Keiko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Komoike, Yoshifumi| Sato, Shuhei| Kanazawa, Susumu|
Abstract A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, -0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, -0.196;p value, 0.0143) and number of deliveries (parameter estimate, -0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s.
Keywords breast cancer mammographic breast density life style body mass index
Amo Type Original Article
Published Date 2013-06
Publication Title Acta Medica Okayama
Volume volume67
Issue issue3
Publisher Okayama University Medical School
Start Page 145
End Page 151
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2013 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 23804137
Web of Sience KeyUT 000320747900003
Related Url http://ousar.lib.okayama-u.ac.jp/metadata/50646
Author Imada, Takako| Matsuoka, Junji| Motoki, Takayuki| Iwamoto, Takayuki| Oomori, Masako| Iha, Sigemichi| Hongo, Toshie| Henmi, Noriko| Makabe, Mikio| Nogami, Hiromi|
Published Date 2012-12-03
Publication Title 岡山医学会雑誌
Volume volume124
Issue issue3
Content Type Journal Article
Author Watanabe, Nobuyuki| Takaoka, Munenori| Sakurama, Kazufumi| Tomono, Yasuko| Hatakeyama, Shinji| Ohmori, Osamu| Motoki, Takayuki| Shirakawa, Yasuhiro| Yamatsuji, Tomoki| Haisa, Minoru| Matsuoka, Junji| Beer, David G.| Nagatsuka, Hitoshi| Tanaka, Noriaki| Naomoto, Yoshio|
Published Date 2010-04-01
Publication Title 岡山医学会雑誌
Volume volume122
Issue issue1
Content Type Journal Article
Author Matsuoka, Junji| Tabuchi, Yoko| Ito, Mitsuya| Ono, Ryoko| Imada, Takako| Matsukawa, Hiroyosi| Motoki, Takayuki| Naomoto, Yoshio| Kanazawa, Susumu|
Published Date 2006-09-01
Publication Title 岡山医学会雑誌
Volume volume118
Issue issue2
Content Type Journal Article
Author Matsuoka, Junji| Tabuchi, Yoko| Ono, Ryoko| Imada, Takako| Umeoka, Tatsuo| Watanabe, Naoki| Motoki, Takayuki| Matsukawa, Hiroyosi| Naomoto, Yoshio| Tanaka, Noriaki| Yanai, Hiroyuki| Omori, Masako|
Published Date 2006-09-01
Publication Title 岡山医学会雑誌
Volume volume118
Issue issue2
Content Type Journal Article
Author Matsuoka, Junji| Tabuchi, Yoko| Ito, Mitsuya| Ono, Ryoko| Imada, Takako| Motoki, Takayuki| Matsukawa, Hiroyosi| Ohmori, Masako| Yanai, Hiroyuki| Naomoto, Yoshio| Tanaka, Noriaki|
Published Date 2006-09-01
Publication Title 岡山医学会雑誌
Volume volume118
Issue issue2
Content Type Journal Article